{"filings":[{"id":111328,"accession_number":"0001213900-26-014722","cik":1960262,"company_name":"LUDWIG ENTERPRISES, INC.","ticker":"LUDG","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Ludwig Enterprises closes $200K convertible note and warrant placement with Alumni Capital LP","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $250K convertible promissory note to Alumni Capital LP; maturity May 4, 2026; net proceeds $200K after original issue discount.","Note convertible at 70% of lowest 20-day VWAP before conversion; warrant for up to 4,166,667 shares at $0.06 per share.","Securities sold under Section 4(a)(2) and Regulation D; unregistered; no commissions paid.","Conversion price set at deep discount to market; terms imply significant dilution upon conversion or warrant exercise.","Proceeds likely used for general working capital; short maturity indicates urgent financing need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4470670.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127931,"accession_number":"0001213900-25-094718","cik":1960262,"company_name":"LUDWIG ENTERPRISES, INC.","ticker":"LUDG","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Ludwig Enterprises appoints Jose Antonio Reyes as Interim CEO effective October 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jose Antonio Reyes, who served as CEO from Aug 2024 to Apr 2025, returns as Interim CEO.","He continues as Senior Head of Global Business Development; no compensatory agreement yet.","Reyes previously served as COO from Feb 2023 to Aug 2024; over 30 years leadership experience.","No arrangements or understandings with any other person regarding his appointment.","No family relationships with other directors/officers, no material interest in transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4470670.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144711,"accession_number":"0001213900-25-085512","cik":1960262,"company_name":"LUDWIG ENTERPRISES, INC.","ticker":"LUDG","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Ludwig Enterprises appoints Corain McGinn as Independent Director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Corain McGinn appointed as Independent Director effective September 5, 2025.","McGinn, age 56, has executive experience at AMD, Microsoft, Merck, Novartis, and Hitachi.","He fills vacancies on the Board; compensation consistent with non-employee directors.","Board anticipates naming McGinn to committees; amendment to follow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":4470670.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144710,"accession_number":"0001213900-25-069395","cik":1960262,"company_name":"LUDWIG ENTERPRISES, INC.","ticker":"LUDG","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CEO Charles T. Todd Jr. resigns effective August 23, 2025; no replacement named yet","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Charles T. Todd Jr. resigned as CEO of Ludwig Enterprises, effective August 23, 2025.","Resignation not due to any disagreement with the Company's operations, policies, or practices.","30-day notice period intended to allow fluid transition and time to appoint a suitable replacement.","No successor has been named as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4470670.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163112,"accession_number":"0001213900-25-057684","cik":1960262,"company_name":"LUDWIG ENTERPRISES, INC.","ticker":"LUDG","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ludwig Enterprises appoints Garth Lees-Rolfe as independent director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Garth Lees-Rolfe appointed independent director effective June 23, 2025.","Over 19 years of finance/accounting experience; currently CFO of ABLi Therapeutics.","Previously CFO of Inhibikase Therapeutics (NASDAQ: IKT) and VP Finance at F-Star (NASDAQ: FSTX).","Spent 16 years at Ernst & Young, most recently as Senior Manager; holds CPA and Chartered Accountant licenses.","No family relationships with existing directors or executive officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":4470670.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163111,"accession_number":"0001213900-25-052068","cik":1960262,"company_name":"LUDWIG ENTERPRISES, INC.","ticker":"LUDG","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Marvin S. Hausman resigns from board, remains Chief Scientific Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Marvin S. Hausman resigned from the Board of Directors on June 5, 2025.","He will continue as Chief Scientific Officer, a position he retains.","Resignation is not due to any disagreement with the Company or management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4470670.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163110,"accession_number":"0001213900-25-048524","cik":1960262,"company_name":"LUDWIG ENTERPRISES, INC.","ticker":"LUDG","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Ludwig Enterprises publishes ASCO abstract on non-invasive breast cancer mRNA test","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Abstract details mRNA signal from buccal cells combined with machine learning for breast cancer screening.","Study analyzed 48 mRNA cytokine biomarkers from non-invasive cheek swabs across 40 U.S. clinical centers.","Top biomarker system achieved F1-score of 0.9, precision 0.892, recall 0.913 (AUC 0.897).","Second system achieved F1-score of 0.892, precision 0.888, recall 0.902 (AUC 0.849).","Research presented at ASCO 2025 Annual Meeting; previously under embargo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":4470670.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163109,"accession_number":"0001213900-25-040453","cik":1960262,"company_name":"LUDWIG ENTERPRISES, INC.","ticker":"LUDG","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Ludwig previews Revealia Breast™ cheek-swab test; Q3 2025 launch expected","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Revealia Breast™ uses mRNA biomarkers and AI from a cheek swab for early cancer detection.","Test is in advanced development with expected release in Q3 2025.","Cites ASBS study: 39.7% non-invasive disease vs 13.2% with traditional management.","First in pipeline of non-invasive mRNA-based cancer screening tests targeting major cancers.","No financial data or revenue projections provided in the release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":4470670.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163108,"accession_number":"0001213900-25-034353","cik":1960262,"company_name":"LUDWIG ENTERPRISES, INC.","ticker":"LUDG","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["1.01","5.02","4.01","7.01","9.01"],"status":"ready","headline":"Ludwig Enterprises appoints Charles Todd Jr. as CEO and Chairman; auditor changes","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Charles Todd Jr., former BioReference EVP who grew revenue from $23M to $1.2B, appointed CEO and Chairman effective April 21, 2025.","Prior CEO Jose Antonio Reyes resigned but remains as Senior Head of Global Business Development; no disagreement cited.","Employment agreement: $25,000/month salary, bonus up to 40% of base, equity awards, unlimited PTO.","Assurance Dimensions resigned as auditor after selling PCAOB issuer division to Stephano Slack; Stephano Slack appointed for FY2025.","Audit reports for 2024 and 2023 had going concern explanatory paragraph; no disagreements or reportable events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4470670.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181019,"accession_number":"0001213900-25-001275","cik":1960262,"company_name":"LUDWIG ENTERPRISES, INC.","ticker":"LUDG","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"Ludwig Enterprises sells Exousia Ai to Marijuana, Inc. for $500K in stock and note","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold 100% of Exousia Ai to Marijuana, Inc. (MAJI) for $500,000 total consideration.","Consideration: 47M shares of MAJI common stock and a $100K promissory note at 8% interest, due Dec 31, 2025.","Ludwig agreed to a lock-up of the MAJI shares until six months after MAJI's uplisting to NASDAQ or NYSE American.","Closing occurred on January 1, 2025, following board approval to focus on Revealia test kit products."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4470670.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214077,"accession_number":"0001903596-24-000596","cik":1960262,"company_name":"LUDWIG ENTERPRISES, INC.","ticker":"LUDG","form_type":"8-K","filed_at":"2024-09-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Ludwig Enterprises announces AI-powered cheek swab cancer screening technology Revealia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Revealia uses AI-driven analysis of mRNA genetic signals from a mail-order non-invasive cheek swab to detect early signs of cancer.","Proprietary Revealia Inflammatory Index (RII) quantifies cancer risk using machine learning that continuously improves with new patient data.","Analysis based on mRNA samples from over 40 multipurpose medical clinics across the United States.","No specific launch date, financial projections, or regulatory status disclosed in the announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":4470670.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214076,"accession_number":"0001903596-24-000592","cik":1960262,"company_name":"LUDWIG ENTERPRISES, INC.","ticker":"LUDG","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Ludwig Enterprises acquires mRNA Neuro Panel patent, serotonin assay IP from Nova Mentis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Acquired U.S. Patent Application 18/705375 and related IP for mRNA neuro panel and serotonin assay from Nova Mentis.","Issued 750,000 shares of common stock to Nova Mentis, subject to one-year lock-up and quarterly sale limits.","Company will pay a 5% royalty on commercialization: 2.5% each to Nova and Hausman until Hausman recovers $245,712 in unpaid consulting.","IP includes data from ASD/Fragile X observational study and serotonin assays from UCF lab of Dr. Kiminobu Sugaya.","Dr. Marvin Hausman, CSO, says IP represents over 10 years of mRNA research; intends to expand beyond breast cancer screening."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4470670.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214075,"accession_number":"0001903596-24-000563","cik":1960262,"company_name":"LUDWIG ENTERPRISES, INC.","ticker":"LUDG","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ludwig Enterprises appoints Jose Antonio Reyes as CEO; Dr. Hausman resigns but remains Director & CSO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Marvin S. Hausman resigned as CEO effective August 20, 2024; no disagreement with company operations.","Jose Antonio Reyes appointed as CEO immediately; background includes roles at BlockScience, IGM Global, and Excelorators.","Dr. Hausman continues to serve as a Director and Chief Science Officer of the company.","Reyes has experience as founder, COO, and business development director across multiple organizations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4470670.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214074,"accession_number":"0001903596-24-000495","cik":1960262,"company_name":"LUDWIG ENTERPRISES, INC.","ticker":"LUDG","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Ludwig to rename Revealia, plans 2024 launch of cancer screening test","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Majority shareholders approved name change to Revealia, Inc., pending FINRA approval.","Plans to launch Revealia cancer screening test (noninvasive cheek swab) to DTC market in 2024.","Intends to apply for OTCQB listing as step toward NASDAQ or CBOE listing.","Over 3000 mRNA samples collected from 40+ U.S. clinics; uses AI for statistical analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4470670.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251414,"accession_number":"0001903596-24-000094","cik":1960262,"company_name":"LUDWIG ENTERPRISES, INC.","ticker":"LUDG","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Ludwig Enterprises enters $5M equity line and $50K promissory note with institutional investor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Common Stock Purchase Agreement for up to $5,000,000; shares sold at 80% of lowest traded price over six days.","Investor received five-year warrant for 2,604,667 shares with anti-dilution and cashless exercise.","Promissory note of $50,000 issued, netting $40,000 after $10,000 OID; matures May 12, 2024, convertible on default.","Equity line capped at $250,000 per notice or 250% of average daily volume; 4.99% beneficial ownership limit.","Registration rights agreement requires filing within 20 days for shares issuable under the agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4470670.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":268963,"accession_number":"0001903596-23-000935","cik":1960262,"company_name":"LUDWIG ENTERPRISES, INC.","ticker":"LUDG","form_type":"8-K","filed_at":"2023-12-01T23:59:59+00:00","items":["1.01","5.02","5.03","9.01"],"status":"ready","headline":"Ludwig Enterprises appoints new CFO and directors; COO resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott J. Silverman appointed CFO via Financial Advisory Services Agreement with EverAsia; monthly payments $8,750 with accrual until $750k raised.","Marvin Hausman (CEO) and Scott Silverman appointed to the Board of Directors, effective immediately.","Thomas Terwilliger resigned as COO on Nov 30, 2023; resignation not due to any disagreement with the company.","Board approved amended and restated bylaws on Nov 15, 2023, providing more comprehensive terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":4470670.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}